ALNY - Alnylam reports positive early Oxlumo data in rare kidney disorder

Alnylam Pharmaceuticals (ALNY) announces positive early results from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). Among 24 patients in ILLUMINATE-A who had been treated with lumasiran for 12 months, 46% (11/24) of patients experienced improvement in nephrocalcinosis grade relative to baseline, 17% (4/24) remained stable, and 13% (3/24) experienced worsening; 25% (6/24) did not have ultrasounds available at 12 months.Of 14 patients with baseline nephrocalcinosis and available ultrasounds, 79% (11/14) showed improvement relative to baseline, and of those who improved, 73% (8/11) improved in both kidneys.Additional data were presented regarding effects on estimated glomerular filtration rate (eGFR) and kidney stone events.PH1 is a rare disorder that mainly affects the kidneys. It results from buildup of a substance called oxalate, which normally is filtered through the kidneys and excreted in the urine. These data were presented at the American

For further details see:

Alnylam reports positive early Oxlumo data in rare kidney disorder